High cost of cancer drugs not always justified

April 30, 2020

A growing number of new cancer drugs have come on the market in recent years, yet the cost of therapies in Europe and the United States have risen. This is driving up healthcare costs, which poses a challenge not only for the Swiss social insurance system, but for patients all over the world. But are the high prices of cancer drugs justified? Does the cost correspond to the particular drug's effectiveness in combating the disease? An international research team from the University of Zurich and Harvard Medical School carried out a study to examine these questions.

Cost comparison of 65 cancer drugs

The scientists - led by Kerstin Noëlle Vokinger, professor at UZH - analyzed the costs of cancer drugs in Switzerland, Germany, England, France and the United States. The prices of 65 new oncology drugs to treat solid tumors and various types of blood cancer were adjusted to calculate the monthly treatment costs for a standard patient.

In a second stage, the researchers investigated whether there is a link between monthly treatment costs and the clinical benefit of cancer drugs for solid tumors. The effectiveness of the drugs, which had been approved by the US and European licensing authorities (the FDA and EMA, respectively), was calculated using two well-established systems for evaluating the clinical benefit of cancer therapies: the American Society of Clinical Oncology Value Framework, and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale.

No correlation between cost and benefit

"Our study clearly shows that, in general, for Switzerland, Germany, England and the United States, there is no association between clinical benefit of a cancer drugs and their prices," explains lead author, Kerstin Vokinger. Only for France a correlation could be found based on one of the clinical benefit assessment systems. "It's also clear that the prices of cancer drugs in the US are significantly higher than in the four European countries, with Americans paying on average approximately twice as much for the same drug."

This is because drug pricing in the US is dictated by the free, unregulated market. In Europe, on the other hand, national authorities negotiate prices with manufacturers. From the European countries analyzed in the study, Switzerland has the second-highest prices after England, while the same drugs are cheaper in Germany and France. It must be kept in mind, however, that NHS England benefits from non-public discounts on certain drugs, so the actual prices may be lower than the official list prices.

Drug prices are not justified

"The pricing of cancer drugs is only partially justified. Drugs that are less effective should be cheaper than those with high efficacy," the UZH professor says. "National authorities should take greater account of the clinical benefits of drugs when negotiating prices, and therapies that provide high clinical benefit should be prioritized in price negotiations." Vokinger firmly believes that this is crucial in order to guarantee patients access to key cancer drugs since countries have only limited financial resources.
-end-
Literature: Kerstin N Vokinger, Thomas J Hwang, Thomas Grischott, Sophie Reichert, Ariadna Tibau, Thomas J Rosemann, Aaron S Kesselheim: Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. The Lancet Oncology, 30 April 2020. DOI: https://doi.org/10.1016/S1470-2045(20)30139-X

University of Zurich

Related Cancer Drugs Articles from Brightsurf:

New analysis method can lead to better cancer drugs
While proteins on the surface of cells are the targets for most drugs, refined methods are needed to analyse how these membrane proteins are organised.

High cost of cancer drugs not always justified
Do high prices of some cancer medicines have a higher benefit than those drugs with lower prices?

What are the environmental impacts of cancer drugs?
Chemotherapeutic drugs, also known as antineoplastic agents, that are prescribed to treat a range of cancer types, enter the aquatic environment via human excretion and wastewater treatment facilities.

Careless cancer cells may be susceptible to future drugs
Could the ability of cancer cells to quickly alter their genome be used as a weapon against malignant tumors?

Towards better anti-cancer drugs
The Bayreuth biochemist Dr. Claus-D. Kuhn and his research team have deciphered how the important human oncogene CDK8 is activated in cells of healthy individuals.

Dozens of non-oncology drugs can kill cancer cells
Researchers tested approximately 4,518 drug compounds on 578 human cancer cell lines and found nearly 50 that have previously unrecognized anti-cancer activity.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

Scientists find a new use for already known anti-cancer drugs
The world scientific community is waging a difficult and prolonged war on cancer.

Using a chip to find better cancer fighting drugs
Kyoto researchers have developed a new 'tumor-on-a-chip' device that can better mimic the environment inside the body, paving the way for improved screening of potential cancer fighting drugs.

Repurposing heart drugs to target cancer cells
This study has highlighted a novel senolytic drug - drug that eliminates senescent cells -- that are currently being used to treat heart conditions that could be repurposed to target cancer cells, and a range of other conditions.

Read More: Cancer Drugs News and Cancer Drugs Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.